



List of Targeted Therapy Drugs Approved for Specific Types of Cancer

The FDA has approved targeted therapy drugs for the treatment of some people with the following types of cancer. Some targeted therapy drugs are listed more than once because they have been approved to treat more than one type of cancer. The generic drug name is listed first, with a brand name in parentheses.

Targeted therapy approved for bladder cancer

- atezolizumab (Tecentriq)
- avelumab (Bavencio)
- enfortumab vedotin-ejfv (Padcev)
- erdafitinib (Balversa)
- nivolumab (Opdivo)
- nogapendekin alfa inbakicept-pmIn (Anktiva)
- pembrolizumab (Keytruda)
- sacituzumab govitecan-hziy (Trodelvy)

Questions?

Targeted therapy approved for brain cancer

- belzutifan (Welireg)
- bevacizumab (Avastin)
- dabrafenib (Tafinlar)
- everolimus (Afinitor)
- tovorafenib (Ojemda)
- trametinib (Mekinist)
- vorasidenib (Voranigo)

Targeted therapy approved for breast cancer

- abemaciclib (Verzenio)
- ado-trastuzumab emtansine (Kadcyla)
- alpelisib (Piqray)
- anastrozole (Arimidex)
- capivasertib (Truqap)
- elacestrant dihydrochloride (Orserdu)
- everolimus (Afinitor)
- exemestane (Aromasin)
- fam-trastuzumab deruxtecan-nxki (Enhertu)
- fulvestrant (Faslodex)
- goserelin acetate (Zoladex)
- lapatinib ditosylate (Tykerb)
- letrozole (Femara)
- margetuximab-cmkb (Margenza)
- neratinib maleate (Nerlynx)
- olaparib (Lynparza)
- palbociclib (Ibrance)
- pembrolizumab (Keytruda)
- pertuzumab (Perjeta)
- pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)
- ribociclib (Kisqali)
- sacituzumab govitecan-hziy (Trodelyv)
- talazoparib tosylate (Talzenna)
- tamoxifen citrate (Soltamox)
- toremifene (Fareston)
- trastuzumab (Herceptin)
- tucatinib (Tukysa)

Targeted therapy approved for cervical cancer

- bevacizumab (Avastin)
- pembrolizumab (Keytruda)
- tisotumab vedotin-tftv (Tivdak)

Targeted therapy approved for colorectal cancer

- adagrasib (Krazati)
- bevacizumab (Avastin)
- cetuximab (Erbix)
- encorafenib (Braftovi)
- fruquintinib (Fruzaqla)
- ipilimumab (Yervoy)
- nivolumab (Opdivo)
- panitumumab (Vectibix)
- pembrolizumab (Keytruda)
- ramucirumab (Cyramza)
- regorafenib (Stivarga)
- tucatinib (Tukysa)
- ziv-aflibercept (Zaltrap)

Targeted therapy approved for dermatofibrosarcoma protuberans

- imatinib mesylate (Gleevec)

Targeted therapy approved for endocrine and neuroendocrine tumors

- avelumab (Bavencio)

- [iobenguane I 131 \(Azedra\)](#)
- [lanreotide acetate \(Somatuline Depot\)](#)
- [lutetium Lu 177-dotatate \(Lutathera\)](#)

Targeted therapy approved for endometrial cancer

- [dostarlimab-gxly \(Jemperli\)](#)
- [durvalumab \(Imfinzi\)](#)
- [lenvatinib mesylate \(Lenvima\)](#)
- [pembrolizumab \(Keytruda\)](#)

Targeted therapy approved for esophageal cancer

- [fam-trastuzumab deruxtecan-nxki \(Enhertu\)](#)
- [ipilimumab \(Yervoy\)](#)
- [nivolumab \(Opdivo\)](#)
- [pembrolizumab \(Keytruda\)](#)
- [ramucirumab \(Cyramza\)](#)
- [tislelizumab-jsgr \(Tevimbra\)](#)
- [trastuzumab \(Herceptin\)](#)

Targeted therapy approved for head and neck cancer

- [cetuximab \(Erbix\)](#)
- [nivolumab \(Opdivo\)](#)
- [pembrolizumab \(Keytruda\)](#)
- [toripalimab-tpzi \(Lqtorzi\)](#)

Targeted therapy approved for gastrointestinal stromal tumor

- [avapritinib \(Ayvakit\)](#)

- [imatinib mesylate \(Gleevec\)](#)
- [regorafenib \(Stivarga\)](#)
- [ripretinib \(Qinlock\)](#)
- [sunitinib malate \(Sutent\)](#)

Targeted therapy approved for giant cell tumor

- [denosumab \(Xgeva\)](#)
- [pexidartinib hydrochloride \(Turalio\)](#)

Targeted therapy approved for kidney cancer

- [avelumab \(Bavencio\)](#)
- [axitinib \(Inlyta\)](#)
- [belzutifan \(Welireg\)](#)
- [bevacizumab \(Avastin\)](#)
- [cabozantinib-s-malate \(Cabometyx\)](#)
- [everolimus \(Afinitor\)](#)
- [ipilimumab \(Yervoy\)](#)
- [lenvatinib mesylate \(Lenvima\)](#)
- [nivolumab \(Opdivo\)](#)
- [pazopanib hydrochloride \(Votrient\)](#)
- [pembrolizumab \(Keytruda\)](#)
- [sorafenib tosylate \(Nexavar\)](#)
- [sunitinib malate \(Sutent\)](#)
- [temsirolimus \(Torisel\)](#)
- [tivozanib hydrochloride \(Fotivda\)](#)

Targeted therapy approved for leukemia

- [acalabrutinib \(Calquence\)](#)
- [alemtuzumab \(Campath\)](#)

- [asciminib hydrochloride \(Scemblix\)](#)
- [avapritinib \(Ayvakit\)](#)
- [blinatumomab \(Blincyto\)](#)
- [bosutinib \(Bosulif\)](#)
- [brexucabtagene autoleucel \(Tecartus\)](#)
- [dasatinib \(Sprycel\)](#)
- [duvelisib \(Copiktra\)](#)
- [enasidenib mesylate \(Idhifa\)](#)
- [gemtuzumab ozogamicin \(Mylotarg\)](#)
- [gilteritinib fumarate \(Xospata\)](#)
- [glasdegib maleate \(Daurismo\)](#)
- [ibrutinib \(Imbruvica\)](#)
- [idelalisib \(Zydelig\)](#)
- [imatinib mesylate \(Gleevec\)](#)
- [inotuzumab ozogamicin \(Besponsa\)](#)
- [ivosidenib \(Tibsovo\)](#)
- [lisocabtagene maraleucel \(Breyanzi\)](#)
- [midostaurin \(Rydapt\)](#)
- [moxetumomab pasudotox-tdfk \(Lumoxiti\)](#)
- [nilotinib \(Tasigna\)](#)
- [obinutuzumab \(Gazyva\)](#)
- [ofatumumab \(Arzerra\)](#)
- [olutasidenib \(Rezlidhia\)](#)
- [pemigatinib \(Pemazyre\)](#)
- [pirtobrutinib \(Jaypirca\)](#)
- [ponatinib hydrochloride \(Iclusig\)](#)
- [quizartinib dihydrochloride \(Vanflyta\)](#)
- [rituximab \(Rituxan\)](#)
- [rituximab and hyaluronidase human \(Rituxan Hycela\)](#)
- [tagraxofusp-erzs \(Elzonris\)](#)

- [tisagenlecleucel \(Kymriah\)](#)
- [tretinoin \(Vesanoid\)](#)
- [venetoclax \(Venclexta\)](#)
- [zanubrutinib \(Brukinsa\)](#)

Targeted therapy approved for liver and bile duct cancer

- [atezolizumab \(Tecentriq\)](#)
- [bevacizumab \(Avastin\)](#)
- [cabozantinib-s-malate \(Cabometyx\)](#)
- [durvalumab \(Imfinzi\)](#)
- [futibatinib \(Lytgobi\)](#)
- [ipilimumab \(Yervoy\)](#)
- [ivosidenib \(Tibsovo\)](#)
- [lenvatinib mesylate \(Lenvima\)](#)
- [nivolumab \(Opdivo\)](#)
- [pembrolizumab \(Keytruda\)](#)
- [pemigatinib \(Pemazyre\)](#)
- [ramucirumab \(Cyramza\)](#)
- [regorafenib \(Stivarga\)](#)
- [sorafenib tosylate \(Nexavar\)](#)
- [tremelimumab-actl \(Imjudo\)](#)

Targeted therapy approved for lung cancer

- [adagrasib \(Krazati\)](#)
- [afatinib dimaleate \(Gilotrif\)](#)
- [alectinib \(Alecensa\)](#)
- [amivantamab-vmjw \(Rybrevant\)](#)
- [atezolizumab \(Tecentriq\)](#)
- [bevacizumab \(Avastin\)](#)

- binimetinib (Mektovi)
- brigatinib (Alunbrig)
- capmatinib hydrochloride (Tabrecta)
- cemiplimab-rwlc (Libtayo)
- ceritinib (Zykadia)
- crizotinib (Xalkori)
- dabrafenib mesylate (Tafinlar)
- dacomitinib (Vizimpro)
- durvalumab (Imfinzi)
- encorafenib (Braftovi)
- entrectinib (Rozlytrek)
- erlotinib hydrochloride (Tarceva)
- fam-trastuzumab deruxtecan-nxki (Enhertu)
- gefitinib (Iressa)
- ipilimumab (Yervoy)
- lazertinib mesylate hydrate (Lazcluze)
- lorlatinib (Lorbrena)
- necitumumab (Portrazza)
- nivolumab (Opdivo)
- osimertinib mesylate (Tagrisso)
- pembrolizumab (Keytruda)
- pralsetinib (Gavreto)
- ramucirumab (Cyramza)
- repotrectinib (Augtyro)
- selpercatinib (Retevmo)
- sotorasib (Lumakras)
- tarlatamab-dlle (Imdelltra)
- tepotinib hydrochloride (Tepmetko)
- trametinib dimethyl sulfoxide (Mekinist)
- tremelimumab-actl (Imjudo)

Targeted therapy approved for lymphoma

- [acalabrutinib \(Calquence\)](#)
- [axicabtagene ciloleucel \(Yescarta\)](#)
- [belinostat \(Beleodaq\)](#)
- [bexarotene \(Targretin\)](#)
- [bortezomib \(Velcade\)](#)
- [brentuximab vedotin \(Adcetris\)](#)
- [brexucabtagene autoleucel \(Tecartus\)](#)
- [crizotinib \(Xalkori\)](#)
- [denileukin diftitox \(Lymphir\)](#)
- [duvelisib \(Copiktra\)](#)
- [epcoritamab-bysp \(Epkinly\)](#)
- [glofitamab-gxbm \(Columvi\)](#)
- [ibritumomab tiuxetan \(Zevalin\)](#)
- [ibrutinib \(Imbruvica\)](#)
- [lisocabtagene maraleucel \(Breyanzi\)](#)
- [loncastuximab tesirine-lpyl \(Zynlonta\)](#)
- [mogamulizumab-kpkc \(Poteligeo\)](#)
- [mosunetuzumab-axgb \(Lunsumio\)](#)
- [nivolumab \(Opdivo\)](#)
- [obinutuzumab \(Gazyva\)](#)
- [pembrolizumab \(Keytruda\)](#)
- [pemigatinib \(Pemazyre\)](#)
- [pirtobrutinib \(Jaypirca\)](#)
- [polatuzumab vedotin-piiq \(Polivy\)](#)
- [pralatrexate \(Folotyn\)](#)
- [rituximab \(Rituxan\)](#)
- [rituximab and hyaluronidase human \(Rituxan Hycela\)](#)
- [romidepsin \(Istodax\)](#)

- [selinexor \(Xpovio\)](#)
- [siltuximab \(Sylvant\)](#)
- [tafasitamab-cxix \(Monjuvi\)](#)
- [tazemetostat hydrobromide \(Tazverik\)](#)
- [tisagenlecleucel \(Kymriah\)](#)
- [venetoclax \(Venclexta\)](#)
- [vorinostat \(Zolinza\)](#)
- [zanubrutinib \(Brukinsa\)](#)

Targeted therapy approved for malignant mesothelioma

- [ipilimumab \(Yervoy\)](#)
- [nivolumab \(Opdivo\)](#)
- [pembrolizumab \(Keytruda\)](#)

Targeted therapy approved for multiple myeloma

- [bortezomib \(Velcade\)](#)
- [carfilzomib \(Kyprolis\)](#)
- [ciltacabtagene autoleucel \(Carvykti\)](#)
- [daratumumab \(Darzalex\)](#)
- [daratumumab and hyaluronidase-fihj \(Darzalex Faspro\)](#)
- [elranatamab-bcmm \(Elrexfio\)](#)
- [elotuzumab \(Empliciti\)](#)
- [idecabtagene vicleucel \(Abecma\)](#)
- [isatuximab-irfc \(Sarclisa\)](#)
- [ixazomib citrate \(Ninlaro\)](#)
- [talquetamab-tgvs \(Talvey\)](#)
- [selinexor \(Xpovio\)](#)
- [teclistamab-cqyv \(Tecvayli\)](#)

Targeted therapy approved for myelodysplastic and myeloproliferative disorders

- fedratinib hydrochloride (Inrebic)
- imatinib mesylate (Gleevec)
- imetelstat sodium (Rytelo)
- ivosidenib (Tibsovo)
- momelotinib dihydrochloride monohydrate (Ojjaara)
- pacritinib citrate (Vonjo)
- pemigatinib (Pemazyre)
- ruxolitinib phosphate (Jakafi)

Targeted therapy approved for neuroblastoma

- dinutuximab (Unituxin)
- naxitamab-gqgk (Danyelza)

Targeted therapy approved for ovarian epithelial, fallopian tube, and primary peritoneal cancers

- bevacizumab (Avastin)
- mirvetuximab soravtansine-gynx (Elahere)
- niraparib tosylate monohydrate (Zejula)
- olaparib (Lynparza)
- rucaparib camsylate (Rubraca)

Targeted therapy approved for pancreatic cancer

- belzutifan (Welireg)
- erlotinib hydrochloride (Tarceva)
- everolimus (Afinitor)

- [olaparib \(Lynparza\)](#)
- [sunitinib malate \(Sutent\)](#)

Targeted therapy approved for plexiform neurofibroma

- [selumetinib sulfate \(Koselugo\)](#)

Targeted therapy approved for prostate cancer

- [abiraterone acetate \(Zytiga\)](#)
- [apalutamide \(Erleada\)](#)
- [bicalutamide \(Casodex\)](#)
- [cabazitaxel \(Jevtana\)](#)
- [darolutamide \(Nubeqa\)](#)
- [degarelix \(Firmagon\)](#)
- [enzalutamide \(Xtandi\)](#)
- [flutamide](#)
- [goserelin acetate \(Zoladex\)](#)
- [leuprolide acetate \(Lupron Depot, Eligard\)](#)
- [leuprolide mesylate \(Camcevi\)](#)
- [lutetium Lu 177 vipivotide tetraxetan \(Pluvicto\)](#)
- [nilutamide \(Nilandron\)](#)
- [niraparib tosylate monohydrate and abiraterone acetate \(Akeega\)](#)
- [olaparib \(Lynparza\)](#)
- [talazoparib tosylate \(Talzenna\)](#)
- [radium 223 dichloride \(Xofigo\)](#)
- [relugolix \(Orgovyx\)](#)
- [rucaparib camsylate \(Rubraca\)](#)

Targeted therapy approved for skin cancer

- [alitretinoin \(Panretin\)](#)

- atezolizumab (Tecentriq)
- avelumab (Bavencio)
- binimetinib (Mektovi)
- cemiplimab-rwlc (Libtayo)
- cobimetinib fumarate (Cotellic)
- dabrafenib mesylate (Tafinlar)
- encorafenib (Braftovi)
- ipilimumab (Yervoy)
- nivolumab (Opdivo)
- nivolumab and relatlimab-rmbw (Opdualag)
- pembrolizumab (Keytruda)
- retifanlimab-dlwr (Zynyz)
- sonidegib (Odomzo)
- tebentafusp-tebn (Kimmtrak)
- trametinib dimethyl sulfoxide (Mekinist)
- vismodegib (Erivedge)
- vemurafenib (Zelboraf)

Targeted therapy approved for soft tissue sarcoma

- afamitresgene autoleucel (Tecelra)
- alitretinoin (Panretin)
- atezolizumab (Tecentriq)
- crizotinib (Xalkori)
- nirogacestat hydrobromide (Ogsiveo)
- pazopanib hydrochloride (Votrient)
- sirolimus protein-bound particles (Fyarro)
- tazemetostat hydrobromide (Tazverik)

Targeted therapy approved for solid tumors anywhere in the body

- dabrafenib mesylate (Tafinlar)
- dostarlimab-gxly (Jemperli)
- entrectinib (Rozlytrek)
- fam-trastuzumab deruxtecan-nxki (Enhertu)
- larotrectinib sulfate (Vitrakvi)
- pembrolizumab (Keytruda)
- repotrectinib (Augtyro)
- selpercatinib (Retevmo)
- trametinib dimethyl sulfoxide (Mekinist)

Targeted therapy approved for stomach (gastric) cancer

- fam-trastuzumab deruxtecan-nxki (Enhertu)
- nivolumab (Opdivo)
- pembrolizumab (Keytruda)
- ramucirumab (Cyramza)
- trastuzumab (Herceptin)

Targeted therapy approved for systemic mastocytosis

- avapritinib (Ayvakit)
- imatinib mesylate (Gleevec)
- midostaurin (Rydapt)

Targeted therapy approved for thyroid cancer

- cabozantinib-s-malate (Cometriq)
- dabrafenib mesylate (Tafinlar)
- lenvatinib mesylate (Lenvima)
- pralsetinib (Gavreto)
- selpercatinib (Retevmo)
- sorafenib tosylate (Nexavar)

- [trametinib dimethyl sulfoxide \(Mekinist\)](#)
- [vandetanib \(Caprelsa\)](#)

Updated: September 24, 2024

If you would like to reproduce some or all of this content, see [Reuse of NCI Information](#) for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., "List of Targeted Therapy Drugs Approved for Specific Types of Cancer was originally published by the National Cancer Institute."